查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1655329

全球液態切片市場

Liquid Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計 2030 年全球液態切片市場規模將達 171 億美元

2024 年全球液態切片市場規模估計為 63 億美元，預計到 2030 年將達到 171 億美元，2024-2030 年分析期間的複合年成長率為 17.9%。液態切片檢測試劑套件是該報告分析的細分市場之一，預計其複合年成長率為 18.0%，到分析期結束時將達到 128 億美元。在分析期內，液態切片儀器部分預計以 16.6% 的複合年成長率成長。

美國市場預計將達到 18 億美元，中國市場年複合成長率將達到 17.2%

預計2024年美國液態切片市場規模將達18億美元。中國是世界第二大經濟體，預計到 2030 年市場規模將達到 26 億美元，2024-2030 年分析期間的複合年成長率為 17.2%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 15.6% 和 15.3%。在歐洲，預計德國的複合年成長率約為 13.1%。

全球液態切片市場-主要趨勢和促進因素摘要

為什麼液態切片可以徹底改變癌症的診斷和治療？

液態切片透過提供一種非侵入性、準確​​且即時的癌症檢測和監測方法，徹底改變了癌症的診斷和治療。與需要透過手術獲取樣本的傳統組織切片檢查不同，液態切片透過分析血液樣本來檢測循環性腫瘤細胞(CTC)、無細胞 DNA (cfDNA) 或與癌症相關的其他生物標記。這種方法可以早期發現癌症、監測病情進展並評估治療效果，同時最大程度地減少患者的不適。液態切片能夠全面了解腫瘤的基因組成，從而徹底改變了個人化醫療，使腫瘤醫生能夠更有效地根據每位患者的需求制定治療方案。隨著對微創、更準確的診斷工具的需求不斷增加，液態切片正迅速被接受為腫瘤學中有價值的工具。

科技進步如何推動液態切片市場的發展？

技術進步在推動液態切片的發展和應用方面發揮關鍵作用，液態切片更加準確、易於獲取和資訊豐富。次世代定序儀(NGS) 和數位 PCR（聚合酵素鏈鎖反應）技術的創新提高了液態切片的敏感性和特異性，使得檢測血液中微量的癌症相關生物標記成為可能。這些進步使得我們能夠識別更廣泛的基因變異，從而更深入地了解腫瘤生物學和治療反應。此外，先進的生物資訊工具的發展正在改善液態切片資料的分析和解釋，從而有助於做出更準確和個人化的治療決策。液態切片檢測方法的不斷改進正在開闢腫瘤學以外的新潛在應用，包括監測器官移植排斥、檢測感染疾病和評估產前遺傳狀況。這些技術創新使液態切片成為精準醫療中更強大、用途更廣泛的工具。

哪些市場趨勢正在影響液態切片的需求？

幾個關鍵的市場趨勢正在影響液態切片的需求。這些包括更加重視個人化醫療、擴大採用非侵入性診斷工具以及擴大腫瘤學以外的液態切片應用。隨著個人化醫療的不斷受到關注，對能夠提供詳細基因資訊以指南標靶治療的診斷工具的需求日益成長。液態切片是這種方法中的寶貴資產，因為它們可以提供對腫瘤遺傳學的即時洞察。非侵入性診斷的趨勢也推動了液態切片的需求。患者和醫療保健提供者正在尋找比傳統組織切片檢查侵入性更小、更舒適的替代方法。此外，液態切片還可應用於其他醫療領域，如移植監測和感染疾病檢測，從而擴大市場機會。液態切片在臨床試驗和藥物開發中的應用越來越廣泛，這進一步促進了其發展，因為它為即時監測治療反應和疾病進展提供了有價值的工具。

推動液態切片市場成長的因素是什麼？

液態切片市場的成長受到多種因素的推動。液態切片為患者提供了一種比傳統切片檢查更友善的替代方法，其主要推動力是全球癌症發病率的上升和對微創診斷方法的需求的增加。基因組和分子診斷技術的進步提高了液態切片的準確性和效用，使其成為對臨床醫生和患者更具吸引力的選擇。個人化醫療的日益採用以及對癌症進展和治療結果的即時監測的需求也促進了市場的擴張。此外，擴大腫瘤學以外的應用，如移植監測和產前檢測，也正在創造新的成長機會。液態切片臨床試驗和研發的增加進一步推動了市場的發展，這繼續檢驗和擴大了這項創新技術的潛在應用。

部分

提供（檢測試劑套件、儀器、服務）；技術（多基因平行分析、單基因分析）；應用（癌症、非癌症）；最終用途（參考實驗室、醫院/醫生實驗室、學術/研究中心、其他最終用途）

調查企業範例（共42家企業）

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP13050

Global Liquid Biopsy Market to Reach US$17.1 Billion by 2030

The global market for Liquid Biopsy estimated at US$6.3 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. Liquid Biopsy Assay Kits, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$12.8 Billion by the end of the analysis period. Growth in the Liquid Biopsy Instruments segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 17.2% CAGR

The Liquid Biopsy market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 17.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.1% CAGR.

Global Liquid Biopsy Market - Key Trends & Drivers Summarized

Why Is Liquid Biopsy Revolutionizing Cancer Diagnosis and Treatment?

Liquid biopsy is revolutionizing the field of cancer diagnosis and treatment by offering a non-invasive, accurate, and real-time method to detect and monitor cancer. Unlike traditional tissue biopsies, which require surgical procedures to obtain samples, liquid biopsies involve analyzing a blood sample to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers associated with cancer. This approach allows for the early detection of cancer, monitoring of disease progression, and assessment of treatment efficacy, all with minimal discomfort to the patient. The ability of liquid biopsies to provide comprehensive insights into the genetic makeup of tumors is transforming personalized medicine, enabling oncologists to tailor treatments to individual patients' needs more effectively. As the demand for less invasive, more accurate diagnostic tools grows, liquid biopsy is rapidly gaining acceptance as a valuable tool in oncology.

How Are Technological Advancements Driving the Liquid Biopsy Market?

Technological advancements are playing a crucial role in driving the growth and adoption of liquid biopsy, making it more accurate, accessible, and informative. Innovations in next-generation sequencing (NGS) and digital PCR (Polymerase Chain Reaction) technologies are enhancing the sensitivity and specificity of liquid biopsies, allowing for the detection of minute amounts of cancer-related biomarkers in the blood. These advancements are enabling the identification of a broader range of genetic mutations, providing deeper insights into tumor biology and treatment response. Additionally, the development of advanced bioinformatics tools is improving the analysis and interpretation of liquid biopsy data, facilitating more precise and personalized treatment decisions. The ongoing refinement of liquid biopsy assays is also expanding their application beyond oncology, with potential uses in monitoring organ transplant rejection, detecting infectious diseases, and assessing prenatal genetic conditions. These technological innovations are making liquid biopsy a more powerful and versatile tool in precision medicine.

What Market Trends Are Shaping the Demand for Liquid Biopsy?

Several key market trends are shaping the demand for liquid biopsy, including the increasing emphasis on personalized medicine, the growing adoption of non-invasive diagnostic tools, and the expansion of liquid biopsy applications beyond oncology. As personalized medicine continues to gain traction, there is a growing need for diagnostic tools that can provide detailed genetic information to guide targeted therapies. Liquid biopsy's ability to offer real-time insights into tumor genetics makes it a valuable asset in this approach. The trend towards non-invasive diagnostics is also driving demand for liquid biopsy, as patients and healthcare providers seek less invasive, more comfortable alternatives to traditional tissue biopsies. Additionally, the potential for liquid biopsy to be used in other areas of medicine, such as transplant monitoring and infectious disease detection, is expanding its market opportunities. The increasing use of liquid biopsy in clinical trials and drug development is further contributing to its growth, as it provides a valuable tool for monitoring treatment response and disease progression in real-time.

What Is Driving the Growth in the Liquid Biopsy Market?

The growth in the liquid biopsy market is driven by several factors. The rising incidence of cancer worldwide and the growing demand for less invasive diagnostic methods are major drivers, as liquid biopsy offers a more patient-friendly alternative to traditional biopsies. Technological advancements in genomics and molecular diagnostics are enhancing the accuracy and utility of liquid biopsy, making it a more attractive option for both clinicians and patients. The increasing adoption of personalized medicine and the need for real-time monitoring of cancer progression and treatment response are also contributing to the market's expansion. Additionally, the broadening of liquid biopsy applications beyond oncology, such as in transplant monitoring and prenatal testing, is creating new opportunities for growth. The growing number of clinical trials and research studies utilizing liquid biopsy is further supporting market development, as these efforts continue to validate and expand the potential uses of this innovative technology.

SCOPE OF STUDY:

The report analyzes the Liquid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Assay Kits, Instruments, Services); Technology (Multi Gene Parallel Analysis, Single Gene Analysis); Application (Cancer, Non-Cancer); End-Use (Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Apostle Inc
  • Biocept, Inc.
  • BioChain Institute, Inc.
  • Biolidics Ltd.
  • CatchGene
  • Elphogene
  • F. Hoffmann-La Roche AG
  • Gencurix, Inc.
  • Genomill Health
  • Guardant Health, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Liquid Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Clinical Applications Propel Growth in the Liquid Biopsy Market
    • Advancements in Circulating Tumor DNA (ctDNA) Technologies Drive Diagnostic Innovations
    • Integration of Liquid Biopsy with Precision Oncology Enhances Treatment Personalization
    • Rising Prevalence of Cancer Worldwide Boosts Demand for Non-Invasive Diagnostic Methods
    • Technological Breakthroughs in Single-Cell Analysis Expand Capabilities of Liquid Biopsy
    • FDA Approvals Accelerate Adoption of Liquid Biopsy Tests in Clinical Settings
    • Collaborations between Biotech Firms and Academic Institutions Fuel Research and Development
    • Growing Investment in Personalized Medicine Spurs Development of Targeted Therapies Using Liquid Biopsy
    • Market Challenges Posed by Sensitivity and Specificity Concerns in Early Cancer Detection
    • Impact of Artificial Intelligence on Enhancing Accuracy and Speed of Liquid Biopsy Analysis
    • Insurance Coverage and Reimbursement Policies Shape the Liquid Biopsy Landscape
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Multi Gene Parallel Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Multi Gene Parallel Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Single Gene Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Non-Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Non-Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Physician Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Hospitals & Physician Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Academic & Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Academic & Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Liquid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Liquid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Offering - Assay Kits, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Liquid Biopsy by Offering - Percentage Breakdown of Value Sales for Assay Kits, Instruments and Services for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Technology - Multi Gene Parallel Analysis and Single Gene Analysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Liquid Biopsy by Technology - Percentage Breakdown of Value Sales for Multi Gene Parallel Analysis and Single Gene Analysis for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by Application - Cancer and Non-Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Liquid Biopsy by Application - Percentage Breakdown of Value Sales for Cancer and Non-Cancer for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Liquid Biopsy by End-Use - Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Liquid Biopsy by End-Use - Percentage Breakdown of Value Sales for Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION